Generation and isolation of antigen-specific T cells

Details Generation and isolation of antigen-specific T cells Generation and isolation of antigen-specific T cells

2011-07-12

2011-07-12

Belyavskyi, Michail (Department: 1644)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Primate cell, per se

C435S375000, C435S405000

Reexamination Certificate

active

07977095

ABSTRACT:
The present invention relates generally to methods for generating, expanding, and isolating antigen-specific T cells. Compositions of antigen-specific T cells activated and expanded by the methods herein are further provided.

REFERENCES:
patent: 5057423 (1991-10-01), Hiserodt et al.
patent: 5081029 (1992-01-01), Zarling et al.
patent: 5190878 (1993-03-01), Wilhelm
patent: 5219740 (1993-06-01), Miller
patent: 5443983 (1995-08-01), Ochoa et al.
patent: 5470730 (1995-11-01), Greenberg et al.
patent: 5547963 (1996-08-01), Poindron et al.
patent: 5595881 (1997-01-01), Kendrick et al.
patent: 5626561 (1997-05-01), Butler
patent: 5635697 (1997-06-01), Shellhammer
patent: 5672505 (1997-09-01), Jones et al.
patent: 5674704 (1997-10-01), Goodwin et al.
patent: 5735279 (1998-04-01), Klaveness et al.
patent: 5766944 (1998-06-01), Ruiz
patent: 5787900 (1998-08-01), Butler
patent: 5804442 (1998-09-01), Romet-Lemonne et al.
patent: 5827642 (1998-10-01), Riddell et al.
patent: 5837477 (1998-11-01), Germain et al.
patent: 5843069 (1998-12-01), Butler
patent: 5858358 (1999-01-01), June et al.
patent: 5874307 (1999-02-01), Ohno et al.
patent: 5883223 (1999-03-01), Gray
patent: 5888807 (1999-03-01), Palsson et al.
patent: 5902745 (1999-05-01), Butler
patent: 5913998 (1999-06-01), Butler
patent: 5942607 (1999-08-01), Freeman et al.
patent: 5962318 (1999-10-01), Rooney et al.
patent: 5962319 (1999-10-01), Ogawa et al.
patent: 5972721 (1999-10-01), Bruno et al.
patent: 5980889 (1999-11-01), Butler
patent: 5985653 (1999-11-01), Armstrong et al.
patent: 6008188 (1999-12-01), Oishi et al.
patent: 6010902 (2000-01-01), Ledbetter et al.
patent: 6074635 (2000-06-01), Abrignani
patent: 6096532 (2000-08-01), Armstrong et al.
patent: 6113901 (2000-09-01), Bluestone
patent: 6120766 (2000-09-01), Hale et al.
patent: 6129916 (2000-10-01), Chang
patent: 6143297 (2000-11-01), Bluestone
patent: 6184043 (2001-02-01), Fodstad et al.
patent: 6197298 (2001-03-01), Chang
patent: 6199654 (2001-03-01), Kojo
patent: 6207453 (2001-03-01), Maass
patent: 6225118 (2001-05-01), Grant et al.
patent: 6274378 (2001-08-01), Steinman et al.
patent: 6316257 (2001-11-01), Flyer et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6355779 (2002-03-01), Goodwin et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6797514 (2004-09-01), Berenson
patent: 6867041 (2005-03-01), Berenson et al.
patent: 6887466 (2005-05-01), June
patent: 6905680 (2005-06-01), June
patent: 7638325 (2009-12-01), June
patent: 2001/0031253 (2001-10-01), Gruenberg
patent: 2002/0076407 (2002-06-01), June et al.
patent: 2002/0090362 (2002-07-01), Stauss
patent: 2002/0115214 (2002-08-01), June et al.
patent: 2002/0155604 (2002-10-01), Ledbetter et al.
patent: 2002/0182730 (2002-12-01), Gruenberg
patent: 2003/0039650 (2003-02-01), Gruenberg
patent: 2003/0099643 (2003-05-01), June et al.
patent: 2003/0119185 (2003-06-01), Berenson
patent: 2003/0124122 (2003-07-01), Berenson et al.
patent: 2003/0134341 (2003-07-01), Gruenberg
patent: 2003/0134415 (2003-07-01), Gruenberg
patent: 2003/0170238 (2003-09-01), Gruenberg et al.
patent: 2003/0175242 (2003-09-01), Gruenberg
patent: 2003/0175272 (2003-09-01), Gruenberg
patent: 2003/0194395 (2003-10-01), Gruenberg et al.
patent: 2003/0224520 (2003-12-01), June et al.
patent: 2003/0235908 (2003-12-01), Berenson et al.
patent: 440 373 (1991-08-01), None
patent: 440 373 (1997-04-01), None
patent: 633 930 (2000-04-01), None
patent: 690125 (2003-04-01), None
patent: WO 94/29436 (1994-12-01), None
patent: WO 97/01304 (1997-01-01), None
patent: WO 97/05233 (1997-02-01), None
patent: WO 97/05239 (1997-02-01), None
patent: WO 97/34618 (1997-09-01), None
patent: WO 9722349 (1997-09-01), None
patent: WO 97/44667 (1997-11-01), None
patent: WO 99/24045 (1999-05-01), None
patent: WO 00/02520 (2000-01-01), None
patent: WO 01/62895 (2001-08-01), None
patent: WO 01/85920 (2001-11-01), None
patent: WO 02/087627 (2002-11-01), None
patent: WO 02/098361 (2002-12-01), None
patent: WO 03/000339 (2003-01-01), None
patent: WO 03/024312 (2003-03-01), None
patent: WO 03/024989 (2003-03-01), None
patent: WO 03/025158 (2003-03-01), None
patent: WO 03/034820 (2003-05-01), None
patent: WO 03/043643 (2003-05-01), None
patent: WO 03/077658 (2003-09-01), None
Campbell et al ., J of Immunol. 2001, v.167, pp. 553-561.
Altman et al., “Phenotypic analysis of antigen-specific T lymphocytes,”Science 274(5284):94-96, 1996.
Arenz et al., “Antigen-independent in vitro expansion of T cells does not affect the T cell receptor Vβ repertoire,”J. Mol. Med. 75:678-686, 1997.
Azuma et al., “B70 antigen is a second ligand for CTLA-4 and CD28,”Nature 366(6450):76-79, Nov. 4, 1993.
Baroja et al., “The Anti-T Cell Monoclonal Antibody 9.3 (Anti-CD28) Provides a Helper Signal and Bypasses the Need for Accessory Cells in T Cell Activation with Immobilized Anti-CD3 and Mitogens,”Cellular Immunology 120:205-217, 1989.
Berenson, “Engraftment After Infusion of CD34+Marrow Cells in Patients With Breast Cancer or Neuroblastoma,”Blood 77(8):1717-1722, Apr. 15, 1991.
Bergstresser et al., “T Cell-Mediated Terminal Maturation of Dendritic Cells,” inDendritic Cell in Fundamental and Clinical Immunology, Ricciardi-Castagnoli (Ed.), Plenum Press, New York, 1997, pp. 65-69.
Bishop et al., “High-Dose Therapy and Peripheral Blood Progenitor Cell Transplantation: Effects of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on the Autograft,”Blood 83(2):610-616, Jan. 15, 1994.
Bonini et al., “HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia,”Science 276:1719-1724, Jun. 13, 1997.
Bonyhadi et al., “Xcellerate: an Autologous T Cell Immunotherapy Approach for Treating B-Cell Lymphocytic Leukemia (B-CLL),”Blood 96(11):837a, Nov. 16, 2000.
Bonyhadi et al., “Autologous T Cell Therapy for B-CLL,”Blood 100(11), Abstract No. 774, Nov. 6, 2002.
Bretscher, “The two-signal model of lymphocyte activation twenty-one years later,”Immunology Today 13(2):74-76, 1992.
Broder, “The Suppressor-Cell Network in Cancer,”The New England Journal of Medicine 299(23):1281-1284, Dec. 7, 1978.
Carlens et al., “Ex vivo T lymphocyte expansion for retroviral transduction: Influence of serum-free media on variations in cell expansion rates and lymphocyte subset distribution,”Experimental Hematology 28:1137-1146, 2000.
Cohen et al., “T-Cell Adoptive Therapy of Tumors: Mechanisms of Improved Therapeutic Performance,”Critical Reviews in Immunology 21:215-248, 2001.
Creson et al., “The Mode and Duration of Anti-CD28 Costimulation Determine Resistance to Infection by Macrophage-Tropic Strains of Human Immunodeficiency Virus Type 1 in Vitro,”Journal Of Virology 73(11):9337-9347, Nov. 1999.
Dal Porto et al., “A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations,”Proc. Natl. Acad. Sci. USA 90:6671-6675, Jul. 1993.
Dietrich et al., “TCR analysis reveals significant repertoire selection during in vitro lymphocyte culture,”International Immunology 9(8):1073-1083, 1997.
Freedman et al., “B7, A B Cell-Restricted Antigen that Identifies Preactivated B Cells,”J. Immunol. 137(10):3260-3267, Nov. 15, 1987.
Freeman et al., “B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells,”J. Immunol. 143(8):2714-2722, Oct. 15, 1989.
Freeman et al., “Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation,”Science 262(5135):909-911, Nov. 5, 1993.
Freeman et al., “Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production,”J. Exp. Med. 178(6):2185-2192, Dec. 1993.
Freeman et al., “Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activat

Affiliated with

Also associated with

Rating

Generation and isolation of antigen-specific T cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Generation and isolation of antigen-specific T cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Generation and isolation of antigen-specific T cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2680296